Corpus GrippeCanadaV3

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Seasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada.

Identifieur interne : 000409 ( Main/Exploration ); précédent : 000408; suivant : 000410

Seasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada.

Auteurs : Rodica Gilca [Canada] ; Elise Fortin ; Charles Frenette ; Yves Longtin ; Marie Gourdeau

Source :

RBID : pubmed:22106208

Descripteurs français

English descriptors

Abstract

Seasonal variations in Clostridium difficile-associated diarrhea (CDAD), with a higher incidence occurring during winter months, have been reported. Although winter epidemics of respiratory viruses may be temporally associated with an increase in CDAD morbidity, we hypothesized that this association is mainly due to increased antibiotic use for respiratory infections. The objective of this study was to evaluate the effect of the two most frequent respiratory viruses (influenza virus and respiratory syncytial virus [RSV]) and antibiotics prescribed for respiratory infections (fluoroquinolones and macrolides) on the CDAD incidence in hospitals in the province of Québec, Canada. A multivariable Box-Jenkins transfer function model was built to relate monthly CDAD incidence to the monthly percentage of positive tests for influenza virus and RSV and monthly fluoroquinolone and macrolide prescriptions over a 4-year period (January 2005 to December 2008). Analysis showed that temporal variations in CDAD incidence followed temporal variations for influenza virus (P = 0.043), RSV (P = 0.004), and macrolide prescription (P = 0.05) time series with an average delay of 1 month and fluoroquinolone prescription time series with an average delay of 2 months (P = 0.01). We conclude that influenza virus and RSV circulation is independently associated with CDAD incidence after controlling for fluoroquinolone and macrolide use. This association was observed at an aggregated level and may be indicative of other phenomena occurring during wintertime.

DOI: 10.1128/AAC.05411-11
PubMed: 22106208


Affiliations:


Links toward previous steps (curation, corpus...)


Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Seasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada.</title>
<author>
<name sortKey="Gilca, Rodica" sort="Gilca, Rodica" uniqKey="Gilca R" first="Rodica" last="Gilca">Rodica Gilca</name>
<affiliation wicri:level="1">
<nlm:affiliation>Institut National de Santé Publique du Québec, Québec, Canada. rodica.gilca@ssss.gouv.qc.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Institut National de Santé Publique du Québec, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Fortin, Elise" sort="Fortin, Elise" uniqKey="Fortin E" first="Elise" last="Fortin">Elise Fortin</name>
</author>
<author>
<name sortKey="Frenette, Charles" sort="Frenette, Charles" uniqKey="Frenette C" first="Charles" last="Frenette">Charles Frenette</name>
</author>
<author>
<name sortKey="Longtin, Yves" sort="Longtin, Yves" uniqKey="Longtin Y" first="Yves" last="Longtin">Yves Longtin</name>
</author>
<author>
<name sortKey="Gourdeau, Marie" sort="Gourdeau, Marie" uniqKey="Gourdeau M" first="Marie" last="Gourdeau">Marie Gourdeau</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="2012">2012</date>
<idno type="RBID">pubmed:22106208</idno>
<idno type="pmid">22106208</idno>
<idno type="doi">10.1128/AAC.05411-11</idno>
<idno type="wicri:Area/Main/Corpus">000479</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000479</idno>
<idno type="wicri:Area/Main/Curation">000479</idno>
<idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000479</idno>
<idno type="wicri:Area/Main/Exploration">000479</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Seasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada.</title>
<author>
<name sortKey="Gilca, Rodica" sort="Gilca, Rodica" uniqKey="Gilca R" first="Rodica" last="Gilca">Rodica Gilca</name>
<affiliation wicri:level="1">
<nlm:affiliation>Institut National de Santé Publique du Québec, Québec, Canada. rodica.gilca@ssss.gouv.qc.ca</nlm:affiliation>
<country xml:lang="fr">Canada</country>
<wicri:regionArea>Institut National de Santé Publique du Québec, Québec</wicri:regionArea>
<wicri:noRegion>Québec</wicri:noRegion>
</affiliation>
</author>
<author>
<name sortKey="Fortin, Elise" sort="Fortin, Elise" uniqKey="Fortin E" first="Elise" last="Fortin">Elise Fortin</name>
</author>
<author>
<name sortKey="Frenette, Charles" sort="Frenette, Charles" uniqKey="Frenette C" first="Charles" last="Frenette">Charles Frenette</name>
</author>
<author>
<name sortKey="Longtin, Yves" sort="Longtin, Yves" uniqKey="Longtin Y" first="Yves" last="Longtin">Yves Longtin</name>
</author>
<author>
<name sortKey="Gourdeau, Marie" sort="Gourdeau, Marie" uniqKey="Gourdeau M" first="Marie" last="Gourdeau">Marie Gourdeau</name>
</author>
</analytic>
<series>
<title level="j">Antimicrobial agents and chemotherapy</title>
<idno type="eISSN">1098-6596</idno>
<imprint>
<date when="2012" type="published">2012</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Anti-Bacterial Agents (pharmacology)</term>
<term>Anti-Bacterial Agents (therapeutic use)</term>
<term>Clostridium Infections (complications)</term>
<term>Clostridium Infections (epidemiology)</term>
<term>Clostridium Infections (microbiology)</term>
<term>Clostridium difficile (drug effects)</term>
<term>Clostridium difficile (isolation & purification)</term>
<term>Community-Acquired Infections (drug therapy)</term>
<term>Drug Resistance, Bacterial</term>
<term>Fluoroquinolones (pharmacology)</term>
<term>Fluoroquinolones (therapeutic use)</term>
<term>Hospitalization (statistics & numerical data)</term>
<term>Humans</term>
<term>Incidence</term>
<term>Influenza, Human (complications)</term>
<term>Influenza, Human (epidemiology)</term>
<term>Influenza, Human (virology)</term>
<term>Macrolides (pharmacology)</term>
<term>Macrolides (therapeutic use)</term>
<term>Orthomyxoviridae (isolation & purification)</term>
<term>Population Surveillance (methods)</term>
<term>Quebec (epidemiology)</term>
<term>Respiratory Syncytial Virus Infections (complications)</term>
<term>Respiratory Syncytial Virus Infections (epidemiology)</term>
<term>Respiratory Syncytial Virus Infections (virology)</term>
<term>Respiratory Syncytial Virus, Human (isolation & purification)</term>
<term>Respiratory Tract Infections (drug therapy)</term>
<term>Seasons</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="KwdFr" xml:lang="fr">
<term>Antibactériens (pharmacologie)</term>
<term>Antibactériens (usage thérapeutique)</term>
<term>Clostridium difficile ()</term>
<term>Clostridium difficile (isolement et purification)</term>
<term>Facteurs temps</term>
<term>Fluoroquinolones (pharmacologie)</term>
<term>Fluoroquinolones (usage thérapeutique)</term>
<term>Grippe humaine ()</term>
<term>Grippe humaine (virologie)</term>
<term>Grippe humaine (épidémiologie)</term>
<term>Hospitalisation ()</term>
<term>Humains</term>
<term>Incidence</term>
<term>Infections communautaires (traitement médicamenteux)</term>
<term>Infections de l'appareil respiratoire (traitement médicamenteux)</term>
<term>Infections à Clostridium ()</term>
<term>Infections à Clostridium (microbiologie)</term>
<term>Infections à Clostridium (épidémiologie)</term>
<term>Infections à virus respiratoire syncytial ()</term>
<term>Infections à virus respiratoire syncytial (virologie)</term>
<term>Infections à virus respiratoire syncytial (épidémiologie)</term>
<term>Macrolides (pharmacologie)</term>
<term>Macrolides (usage thérapeutique)</term>
<term>Orthomyxoviridae (isolement et purification)</term>
<term>Québec (épidémiologie)</term>
<term>Résistance bactérienne aux médicaments</term>
<term>Saisons</term>
<term>Surveillance de la population ()</term>
<term>Virus respiratoire syncytial humain (isolement et purification)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="pharmacology" xml:lang="en">
<term>Anti-Bacterial Agents</term>
<term>Fluoroquinolones</term>
<term>Macrolides</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en">
<term>Anti-Bacterial Agents</term>
<term>Fluoroquinolones</term>
<term>Macrolides</term>
</keywords>
<keywords scheme="MESH" type="geographic" qualifier="epidemiology" xml:lang="en">
<term>Quebec</term>
</keywords>
<keywords scheme="MESH" qualifier="complications" xml:lang="en">
<term>Clostridium Infections</term>
<term>Influenza, Human</term>
<term>Respiratory Syncytial Virus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Clostridium difficile</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Community-Acquired Infections</term>
<term>Respiratory Tract Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="epidemiology" xml:lang="en">
<term>Clostridium Infections</term>
<term>Influenza, Human</term>
<term>Respiratory Syncytial Virus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="isolation & purification" xml:lang="en">
<term>Clostridium difficile</term>
<term>Orthomyxoviridae</term>
<term>Respiratory Syncytial Virus, Human</term>
</keywords>
<keywords scheme="MESH" qualifier="isolement et purification" xml:lang="fr">
<term>Clostridium difficile</term>
<term>Orthomyxoviridae</term>
<term>Virus respiratoire syncytial humain</term>
</keywords>
<keywords scheme="MESH" qualifier="methods" xml:lang="en">
<term>Population Surveillance</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiologie" xml:lang="fr">
<term>Infections à Clostridium</term>
</keywords>
<keywords scheme="MESH" qualifier="microbiology" xml:lang="en">
<term>Clostridium Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="pharmacologie" xml:lang="fr">
<term>Antibactériens</term>
<term>Fluoroquinolones</term>
<term>Macrolides</term>
</keywords>
<keywords scheme="MESH" qualifier="statistics & numerical data" xml:lang="en">
<term>Hospitalization</term>
</keywords>
<keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr">
<term>Infections communautaires</term>
<term>Infections de l'appareil respiratoire</term>
</keywords>
<keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr">
<term>Antibactériens</term>
<term>Fluoroquinolones</term>
<term>Macrolides</term>
</keywords>
<keywords scheme="MESH" qualifier="virologie" xml:lang="fr">
<term>Grippe humaine</term>
<term>Infections à virus respiratoire syncytial</term>
</keywords>
<keywords scheme="MESH" qualifier="virology" xml:lang="en">
<term>Influenza, Human</term>
<term>Respiratory Syncytial Virus Infections</term>
</keywords>
<keywords scheme="MESH" qualifier="épidémiologie" xml:lang="fr">
<term>Grippe humaine</term>
<term>Infections à Clostridium</term>
<term>Infections à virus respiratoire syncytial</term>
<term>Québec</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Drug Resistance, Bacterial</term>
<term>Humans</term>
<term>Incidence</term>
<term>Seasons</term>
<term>Time Factors</term>
</keywords>
<keywords scheme="MESH" xml:lang="fr">
<term>Clostridium difficile</term>
<term>Facteurs temps</term>
<term>Grippe humaine</term>
<term>Hospitalisation</term>
<term>Humains</term>
<term>Incidence</term>
<term>Infections à Clostridium</term>
<term>Infections à virus respiratoire syncytial</term>
<term>Résistance bactérienne aux médicaments</term>
<term>Saisons</term>
<term>Surveillance de la population</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Seasonal variations in Clostridium difficile-associated diarrhea (CDAD), with a higher incidence occurring during winter months, have been reported. Although winter epidemics of respiratory viruses may be temporally associated with an increase in CDAD morbidity, we hypothesized that this association is mainly due to increased antibiotic use for respiratory infections. The objective of this study was to evaluate the effect of the two most frequent respiratory viruses (influenza virus and respiratory syncytial virus [RSV]) and antibiotics prescribed for respiratory infections (fluoroquinolones and macrolides) on the CDAD incidence in hospitals in the province of Québec, Canada. A multivariable Box-Jenkins transfer function model was built to relate monthly CDAD incidence to the monthly percentage of positive tests for influenza virus and RSV and monthly fluoroquinolone and macrolide prescriptions over a 4-year period (January 2005 to December 2008). Analysis showed that temporal variations in CDAD incidence followed temporal variations for influenza virus (P = 0.043), RSV (P = 0.004), and macrolide prescription (P = 0.05) time series with an average delay of 1 month and fluoroquinolone prescription time series with an average delay of 2 months (P = 0.01). We conclude that influenza virus and RSV circulation is independently associated with CDAD incidence after controlling for fluoroquinolone and macrolide use. This association was observed at an aggregated level and may be indicative of other phenomena occurring during wintertime.</div>
</front>
</TEI>
<pubmed>
<MedlineCitation Status="MEDLINE" Owner="NLM">
<PMID Version="1">22106208</PMID>
<DateCompleted>
<Year>2012</Year>
<Month>05</Month>
<Day>25</Day>
</DateCompleted>
<DateRevised>
<Year>2018</Year>
<Month>11</Month>
<Day>13</Day>
</DateRevised>
<Article PubModel="Print-Electronic">
<Journal>
<ISSN IssnType="Electronic">1098-6596</ISSN>
<JournalIssue CitedMedium="Internet">
<Volume>56</Volume>
<Issue>2</Issue>
<PubDate>
<Year>2012</Year>
<Month>Feb</Month>
</PubDate>
</JournalIssue>
<Title>Antimicrobial agents and chemotherapy</Title>
<ISOAbbreviation>Antimicrob. Agents Chemother.</ISOAbbreviation>
</Journal>
<ArticleTitle>Seasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada.</ArticleTitle>
<Pagination>
<MedlinePgn>639-46</MedlinePgn>
</Pagination>
<ELocationID EIdType="doi" ValidYN="Y">10.1128/AAC.05411-11</ELocationID>
<Abstract>
<AbstractText>Seasonal variations in Clostridium difficile-associated diarrhea (CDAD), with a higher incidence occurring during winter months, have been reported. Although winter epidemics of respiratory viruses may be temporally associated with an increase in CDAD morbidity, we hypothesized that this association is mainly due to increased antibiotic use for respiratory infections. The objective of this study was to evaluate the effect of the two most frequent respiratory viruses (influenza virus and respiratory syncytial virus [RSV]) and antibiotics prescribed for respiratory infections (fluoroquinolones and macrolides) on the CDAD incidence in hospitals in the province of Québec, Canada. A multivariable Box-Jenkins transfer function model was built to relate monthly CDAD incidence to the monthly percentage of positive tests for influenza virus and RSV and monthly fluoroquinolone and macrolide prescriptions over a 4-year period (January 2005 to December 2008). Analysis showed that temporal variations in CDAD incidence followed temporal variations for influenza virus (P = 0.043), RSV (P = 0.004), and macrolide prescription (P = 0.05) time series with an average delay of 1 month and fluoroquinolone prescription time series with an average delay of 2 months (P = 0.01). We conclude that influenza virus and RSV circulation is independently associated with CDAD incidence after controlling for fluoroquinolone and macrolide use. This association was observed at an aggregated level and may be indicative of other phenomena occurring during wintertime.</AbstractText>
</Abstract>
<AuthorList CompleteYN="Y">
<Author ValidYN="Y">
<LastName>Gilca</LastName>
<ForeName>Rodica</ForeName>
<Initials>R</Initials>
<AffiliationInfo>
<Affiliation>Institut National de Santé Publique du Québec, Québec, Canada. rodica.gilca@ssss.gouv.qc.ca</Affiliation>
</AffiliationInfo>
</Author>
<Author ValidYN="Y">
<LastName>Fortin</LastName>
<ForeName>Elise</ForeName>
<Initials>E</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Frenette</LastName>
<ForeName>Charles</ForeName>
<Initials>C</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Longtin</LastName>
<ForeName>Yves</ForeName>
<Initials>Y</Initials>
</Author>
<Author ValidYN="Y">
<LastName>Gourdeau</LastName>
<ForeName>Marie</ForeName>
<Initials>M</Initials>
</Author>
</AuthorList>
<Language>eng</Language>
<PublicationTypeList>
<PublicationType UI="D016428">Journal Article</PublicationType>
</PublicationTypeList>
<ArticleDate DateType="Electronic">
<Year>2011</Year>
<Month>11</Month>
<Day>21</Day>
</ArticleDate>
</Article>
<MedlineJournalInfo>
<Country>United States</Country>
<MedlineTA>Antimicrob Agents Chemother</MedlineTA>
<NlmUniqueID>0315061</NlmUniqueID>
<ISSNLinking>0066-4804</ISSNLinking>
</MedlineJournalInfo>
<ChemicalList>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D024841">Fluoroquinolones</NameOfSubstance>
</Chemical>
<Chemical>
<RegistryNumber>0</RegistryNumber>
<NameOfSubstance UI="D018942">Macrolides</NameOfSubstance>
</Chemical>
</ChemicalList>
<CitationSubset>IM</CitationSubset>
<MeshHeadingList>
<MeshHeading>
<DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D003015" MajorTopicYN="N">Clostridium Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="Y">complications</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000382" MajorTopicYN="N">microbiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D016360" MajorTopicYN="N">Clostridium difficile</DescriptorName>
<QualifierName UI="Q000187" MajorTopicYN="N">drug effects</QualifierName>
<QualifierName UI="Q000302" MajorTopicYN="Y">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D017714" MajorTopicYN="N">Community-Acquired Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D024881" MajorTopicYN="N">Drug Resistance, Bacterial</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D024841" MajorTopicYN="N">Fluoroquinolones</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName>
<QualifierName UI="Q000706" MajorTopicYN="N">statistics & numerical data</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D015994" MajorTopicYN="N">Incidence</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D007251" MajorTopicYN="N">Influenza, Human</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018942" MajorTopicYN="N">Macrolides</DescriptorName>
<QualifierName UI="Q000494" MajorTopicYN="N">pharmacology</QualifierName>
<QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D009975" MajorTopicYN="N">Orthomyxoviridae</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011159" MajorTopicYN="N">Population Surveillance</DescriptorName>
<QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D011792" MajorTopicYN="N" Type="Geographic">Quebec</DescriptorName>
<QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018357" MajorTopicYN="N">Respiratory Syncytial Virus Infections</DescriptorName>
<QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName>
<QualifierName UI="Q000453" MajorTopicYN="Y">epidemiology</QualifierName>
<QualifierName UI="Q000821" MajorTopicYN="N">virology</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D018113" MajorTopicYN="N">Respiratory Syncytial Virus, Human</DescriptorName>
<QualifierName UI="Q000302" MajorTopicYN="N">isolation & purification</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012141" MajorTopicYN="N">Respiratory Tract Infections</DescriptorName>
<QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D012621" MajorTopicYN="Y">Seasons</DescriptorName>
</MeshHeading>
<MeshHeading>
<DescriptorName UI="D013997" MajorTopicYN="N">Time Factors</DescriptorName>
</MeshHeading>
</MeshHeadingList>
</MedlineCitation>
<PubmedData>
<History>
<PubMedPubDate PubStatus="entrez">
<Year>2011</Year>
<Month>11</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="pubmed">
<Year>2011</Year>
<Month>11</Month>
<Day>23</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
<PubMedPubDate PubStatus="medline">
<Year>2012</Year>
<Month>5</Month>
<Day>26</Day>
<Hour>6</Hour>
<Minute>0</Minute>
</PubMedPubDate>
</History>
<PublicationStatus>ppublish</PublicationStatus>
<ArticleIdList>
<ArticleId IdType="pubmed">22106208</ArticleId>
<ArticleId IdType="pii">AAC.05411-11</ArticleId>
<ArticleId IdType="doi">10.1128/AAC.05411-11</ArticleId>
<ArticleId IdType="pmc">PMC3264229</ArticleId>
</ArticleIdList>
<ReferenceList>
<Reference>
<Citation>Int J Antimicrob Agents. 2000 Feb;14(1):21-31</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">10717497</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2011 Nov 3;365(18):1693-703</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">22047560</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Infect Dis. 2004 May 1;189(9):1585-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15116293</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Emerg Infect Dis. 2004 Aug;10(8):1432-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15496245</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Epidemiol. 1981 Mar;113(3):215-26</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">6258426</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Epidemiol. 1991 Sep;20(3):808-15</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">1955267</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Int J Epidemiol. 1994 Aug;23(4):849-55</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8002201</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Stat Methods Med Res. 1996 Mar;5(1):3-22</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">8743076</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Infect Dis. 1998 May;26(5):1027-34; quiz 1035-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">9597221</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2005 Apr 28;352(17):1749-59</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">15858184</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Infect Dis. 2005 Nov 1;41(9):1254-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16206099</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2005 Dec 8;353(23):2442-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16322602</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>N Engl J Med. 2005 Dec 8;353(23):2433-41</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16322603</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Microbiol Infect. 2006 Oct;12 Suppl 6:2-18</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">16965399</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Antimicrob Agents Chemother. 2006 Oct;50(10):3473-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17005836</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Clin Infect Dis. 2007 Jan 15;44(2):238-44</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17173224</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Infect Control Hosp Epidemiol. 2007 Feb;28(2):131-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17265393</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Emerg Infect Dis. 2006 Nov;12(11):1730-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17283624</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Emerg Infect Dis. 2007 May;13(5):761-3</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17553260</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Infect Control Hosp Epidemiol. 2007 Aug;28(8):920-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17620238</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Hosp Infect. 2007 Aug;66(4):395-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17662506</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Hosp Infect. 2007 Aug;66(4):394-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">17669553</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Proc Am Thorac Soc. 2007 Dec;4(8):591-6</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18073388</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Med Microbiol. 2008 Jun;57(Pt 6):784-9</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18480338</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Antimicrob Chemother. 2008 Sep;62(3):593-600</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18467307</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Antimicrob Chemother. 2008 Sep;62(3):601-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18468995</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>CMAJ. 2008 Oct 7;179(8):767-72</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">18838451</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Emerg Infect Dis. 2009 Feb;15(2):343-4</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19193291</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Antimicrob Agents Chemother. 2009 May;53(5):2082-8</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19289520</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Emerg Infect Dis. 2009 May;15(5):802-5</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19402975</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Clin Virol. 2009 Oct;46(2):129-33</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19665425</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Am J Epidemiol. 2009 Oct 1;170(7):925-36</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19679751</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Anaerobe. 2009 Dec;15(6):256-60</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">19778624</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Euro Surveill. 2010 Feb 4;15(5). pii: 19479</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20144444</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Infect Control Hosp Epidemiol. 2010 Apr;31(4):382-7</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20175682</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Respirology. 2010 Apr;15(3):536-42</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20415983</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Infect Control Hosp Epidemiol. 2010 Sep;31(9):939-47</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20677973</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Chest. 2010 Oct;138(4):896-904</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">20435659</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>Lancet. 2011 Jan 1;377(9759):63-73</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">21084111</ArticleId>
</ArticleIdList>
</Reference>
<Reference>
<Citation>J Antimicrob Chemother. 2003 Mar;51(3):599-603</Citation>
<ArticleIdList>
<ArticleId IdType="pubmed">12615860</ArticleId>
</ArticleIdList>
</Reference>
</ReferenceList>
</PubmedData>
</pubmed>
<affiliations>
<list>
<country>
<li>Canada</li>
</country>
</list>
<tree>
<noCountry>
<name sortKey="Fortin, Elise" sort="Fortin, Elise" uniqKey="Fortin E" first="Elise" last="Fortin">Elise Fortin</name>
<name sortKey="Frenette, Charles" sort="Frenette, Charles" uniqKey="Frenette C" first="Charles" last="Frenette">Charles Frenette</name>
<name sortKey="Gourdeau, Marie" sort="Gourdeau, Marie" uniqKey="Gourdeau M" first="Marie" last="Gourdeau">Marie Gourdeau</name>
<name sortKey="Longtin, Yves" sort="Longtin, Yves" uniqKey="Longtin Y" first="Yves" last="Longtin">Yves Longtin</name>
</noCountry>
<country name="Canada">
<noRegion>
<name sortKey="Gilca, Rodica" sort="Gilca, Rodica" uniqKey="Gilca R" first="Rodica" last="Gilca">Rodica Gilca</name>
</noRegion>
</country>
</tree>
</affiliations>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Sante/explor/GrippeCanadaV3/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000409 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000409 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Sante
   |area=    GrippeCanadaV3
   |flux=    Main
   |étape=   Exploration
   |type=    RBID
   |clé=     pubmed:22106208
   |texte=   Seasonal variations in Clostridium difficile infections are associated with influenza and respiratory syncytial virus activity independently of antibiotic prescriptions: a time series analysis in Quebec, Canada.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i   -Sk "pubmed:22106208" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd   \
       | NlmPubMed2Wicri -a GrippeCanadaV3 

Wicri

This area was generated with Dilib version V0.6.35.
Data generation: Tue Jul 7 13:36:58 2020. Site generation: Sat Sep 26 07:06:42 2020